Article Text

Download PDFPDF

192 ‘Immune-brain’: a case series of cognitive dysfunction/decline in cancer patients on immunotherapy
  1. Sarah Gillett,
  2. Ximena Jordan-Bruno,
  3. Hibba Rehman,
  4. Alissa Thomas and
  5. Sarah Gillett
  1. University of Vermont Medical Center, Burlington, VT, USA


Background Immunotherapy agents are now the standard of care for many types of malignancies and use of checkpoint inhibitor immunotherapy (IO) is widespread across oncology. Cognitive dysfunction/decline (CD) is a well-known side effect of conventional chemotherapy (i.e. ‘chemo-brain’), but the neuro-cognitive impact of checkpoint inhibitor immunotherapy (IO) is not well described, despite the known potential for inflammatory neurotoxicities and encephalitis. Though high grade neurologic events are reported in <1% of patients receiving IO, less severe or possibly transient neurocognitive effects that do not lead to formal neuropsychological evaluation are probably under-reported. Combination of IO with other anti-cancer modalities like cytotoxic chemotherapy and radiation could theoretically compound neurotoxicity through neuroinflammation.

Methods From January 2015-Decmber 2018 at University of Vermont Medical Center, we retrospectively identified cancer patients who received at least one infusion of IO and had a concurrent diagnosis of CD on the problem list, medical history, or billing codes. We used the search terms: cognitive impairment, mild cognitive impairment, neurodegenerative cognitive impairment, memory change/memory deficit/memory difficulty/memory impairment, altered mental status, or encephalopathy to define cognitive impairment. We manually reviewed the charts of all patients meeting this criteria and excluded patients with an alternative diagnosis that was causal for CD (stroke, sepsis, seizure, brain tumor).

Results We identified 55 patients and excluded 16 for CD before IO started, 23 with toxic/metabolic causes (including stroke, sepsis, medications, seizures), 4 for primary central nervous system malignancy, and 6 for CD related to new or worsening brain metastases. Six had CD possibly related to IO (table 1). Most had also received chemotherapy either concurrently or prior to starting IO, but two patients had only ever received IO cancer therapy. Four of the six had documented MMSE or neuropsychological testing. On careful chart review, no alternative diagnosis was identified as clearly causal for the change in cognition.

Abstract 192 Table 1

Patient Characteristics

Conclusions Patients receiving IO cancer therapy do report CD, which has not been broadly described. Though our data is corollary, it opens the question as to whether prospective pre- and post-treatment cognitive monitoring may identify more patients with neurocognitive symptoms related to immunotherapy. Future research is needed to report incidence of potential IO-related CD and to develop preventative or therapeutic strategies.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.